We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. At week 16, 55.9% of the risankizumab group and 5.1% of ...
"Ulcerative colitis is a chronic, unpredictable and sometimes debilitating disease, and people living with the condition need sustained symptom relief," said Edouard Louis, M.D., Ph.D., professor and ...
Oregon Medical Research Center in Portland, Oregon, has led a phase 2 trial in moderate-to-severe plaque psoriasis that ...
- CHMP positive opinion is based on results from three Phase 3 studies: two for induction and one for maintenance 1,2 - Crohn's disease is a chronic, systemic disease that manifests as inflammation ...
"At AbbVie, patients are at the heart of everything we do," said Kori Wallace, M.D., Ph.D., vice president, immunology clinical development, AbbVie. "We are motivated to bring new treatment options to ...
Submissions are supported by two Phase 3 clinical trials demonstrating risankizumab achieved the primary endpoint of clinical remission (per Adapted Mayo Score) and key secondary endpoints as an ...
MONTREAL, April 18, 2019 /CNW/ - AbbVie (NYSE: ABBV), a global research and development-based biopharmaceutical company, announced today that Health Canada has approved SKYRIZI™ (risankizumab) for the ...
NORTH CHICAGO, Ill., May 31, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) adopted a ...
The positive opinion is based on results from two pivotal Phase 3 trials, INSPIRE and COMMAND, that evaluated the efficacy and safety of risankizumab in adults with moderately to severely active ...
The objective of the Phase 3 trial is to evaluate the efficacy and safety of risankizumab 180 mg or 360 mg as maintenance therapy versus withdrawal from risankizumab treatment (control) in patients ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback